clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Takagi M et al. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. 2015 Drug Metab. Pharmacokinet. pmid:26195223
Shallom SJ et al. New Real-Time PCR Assays for Detection of Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Group. 2015 J. Clin. Microbiol. pmid:26269619
Zagari RM et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. 2015 Dig Liver Dis pmid:26253555
Sprague J et al. Cutaneous infection with Mycobacterium kansasii in a patient with myelodysplastic syndrome and Sweet syndrome. 2015 Cutis pmid:26244358
Sharara AI et al. Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. 2015 Aliment. Pharmacol. Ther. pmid:26238584
Graham DY and Gisbert JP Letter: clarithromycin dose for H. pylori therapy remains unresolved. 2015 Aliment. Pharmacol. Ther. pmid:26238583
Navarro-Jarabo JM et al. Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. 2015 Digestion pmid:26227669
Ufuk A et al. In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383. 2015 Pharm. Res. pmid:26224396
Cohen O et al. Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori. 2015 Rheumatol. Int. pmid:26210999
Antony SJ Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host. 2015 Infect Disord Drug Targets pmid:26205798
Chowdhary M et al. Intracranial abscess due to Mycobacterium avium complex in an immunocompetent host: a case report. 2015 BMC Infect. Dis. pmid:26201464
Zheng H et al. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure. 2015 Sex Transm Dis pmid:25668641
Jung IY et al. A case of bronchiolitis obliterans organizing pneumonia in an HIV-infected Korean patient successfully treated with clarithromycin. 2015 BMC Infect. Dis. pmid:26201392
Kasai A et al. Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011. 2015 J. Med. Microbiol. pmid:25934551
Chou HW et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. 2015 Clin. Infect. Dis. pmid:25409476
Flores-Gonzalez JC et al. [Etiology, clinical presentation and outcome of severe viral acute childhood encephalitis (ECOVE study)]. 2015 Rev Neurol pmid:26108903
Jeong BH et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. 2015 Am. J. Respir. Crit. Care Med. pmid:25393520
Hill FJ et al. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. 2015 BMJ Case Rep pmid:26106178
Yu T et al. Study on clarithromycin lactobionate based dual selector systems for the enantioseparation of basic drugs in capillary electrophoresis. 2015 J Sep Sci pmid:26097042
Trotti LM et al. Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. 2015 Ann. Neurol. pmid:26094838
Tai WC et al. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication. 2015 Biomed Res Int pmid:26090428
Nguyen AT et al. Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections. 2015 Cornea pmid:26075451
Fujiki S et al. Suppressed Release of Clarithromycin from Tablets by Crystalline Phase Transition of Metastable Polymorph Form I. 2015 J Pharm Sci pmid:26053058
Zeng M et al. Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study. 2015 BMC Immunol. pmid:26047816
Ito A et al. Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital. 2015 J. Med. Microbiol. pmid:25934550
AktaÅŸ B et al. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. 2015 Eur J Gastroenterol Hepatol pmid:25919773
Lam A et al. Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells. 2015 Int Forum Allergy Rhinol pmid:25907295
Luo RF et al. Rapid Detection of Acquired and Inducible Clarithromycin Resistance in Mycobacterium abscessus Group by a Simple Real-Time PCR Assay. 2015 J. Clin. Microbiol. pmid:25903572
Kumarihamy KW et al. A rare complication of pulmonary tuberculosis: a case report. 2015 BMC Res Notes pmid:25888831
Almeida N et al. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? 2015 BMC Gastroenterol pmid:25886722
Kim JS et al. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. 2015 J. Gastroenterol. Hepatol. pmid:25867718
Bouilhat N et al. High-level primary clarithromycin resistance of Helicobacter pylori in Morocco: a prospective multicenter molecular study. 2015 Helicobacter pmid:25735573
Guzman Vinasco L et al. Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man. 2015 BMJ Case Rep pmid:25733094
Mitsui Y et al. Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication. 2015 Clin J Gastroenterol pmid:25733031
Ben Chaabane N and Al-Adhba HS Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial. 2015 Indian J Gastroenterol pmid:25721770
Townsell MY et al. Pathology in practice. Canine distemper virus disease in a dog. 2015 J. Am. Vet. Med. Assoc. pmid:25719842
Scherübl H et al. [What is new in treating Helicobacter pylori infection?]. 2015 Dtsch. Med. Wochenschr. pmid:25704525
Aoki H et al. Clarithromycin highly-loaded gastro-floating fine granules prepared by high-shear melt granulation can enhance the efficacy of Helicobacter pylori eradication. 2015 Eur J Pharm Biopharm pmid:25703356
Baysal B et al. Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients. 2015 Turk J Gastroenterol pmid:25698264
Burton AJ et al. Efficacy of liposomal gentamicin against Rhodococcus equi in a mouse infection model and colocalization with R. equi in equine alveolar macrophages. 2015 Vet. Microbiol. pmid:25666452
Cowan R et al. Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients? 2015 PLoS Negl Trop Dis pmid:25658304
Blix HS et al. Antibiotic prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance? 2015 Epidemiol. Infect. pmid:25388750
Brown-Elliott BA et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. 2015 J. Clin. Microbiol. pmid:25653399
Brown-Elliott BA et al. Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. 2015 J. Clin. Microbiol. pmid:25568437
Amiri M Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura. 2015 Glob J Health Sci pmid:26925898
Haghi M et al. Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. 2015 Pharm. Res. pmid:25537341
Kam Y et al. Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". 2015 Int. J. Cancer pmid:25156304
Li DQ et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. 2015 CMAJ pmid:25534598
Yildizoglu U et al. Effect of antibiotic use on bacterial flora of tonsil core in patients with recurrent tonsillitis. 2015 Eur Arch Otorhinolaryngol pmid:25510984
Zhang L et al. [Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection]. 2015 Zhonghua Nei Ke Za Zhi pmid:26887366
Montes M et al. Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response. 2015 Helicobacter pmid:25382231
Wang B et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. 2015 Helicobacter pmid:25381839
Yoon K et al. Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea. 2015 J. Gastroenterol. Hepatol. pmid:25363555
Frew JW and Nguyen RT Tattoo-associated mycobacterial infections: an emerging public health issue. 2015 Med. J. Aust. pmid:26852055
Park JB et al. Modulation of microenvironmental pH and utilization of alkalizers in crystalline solid dispersion for enhanced solubility and stability of clarithromicin. 2015 Arch. Pharm. Res. pmid:25213008
Anton E et al. Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. 2015 Antimicrob. Agents Chemother. pmid:26711765
Bang CS et al. Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection. 2015 Gut Liver pmid:25167799
Hasegawa T et al. Image of the month: Disseminated Nontuberculous Mycobacteriosis. 2015 Am. J. Gastroenterol. pmid:26673493
Stepney R et al. Case report: Improved gum health. 2015 Br Dent J pmid:26657423
Winters N et al. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. 2015 Eur. Respir. J. pmid:26381514
Alimadadi M et al. Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease. 2015 Iran J Kidney Dis pmid:26552348
Dogan Z et al. The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study. 2015 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:24993741
Karpiński TM et al. Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland. 2015 Acta Microbiol Immunol Hung pmid:26551571
John A et al. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection? 2015 Indian J Gastroenterol pmid:26541342
Mel-Hennawi D and Ahmed MR Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. 2015 J Laryngol Otol pmid:26521817
Parra D et al. In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. 2015 BMC Microbiol. pmid:26518881
Xing J et al. The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans. 2015 Anal. Chim. Acta pmid:26515003
Demirci H et al. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. 2015 Turk J Gastroenterol pmid:26510082
Mesgarpour B et al. A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. 2015 Lipids Health Dis pmid:26497728
Namkoong H et al. Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. 2015 BMC Pulm Med pmid:26496968
Wang CH et al. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. 2015 World J. Gastroenterol. pmid:26494972
Bérard A et al. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. 2015 Pharmacoepidemiol Drug Saf pmid:26513406
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Weiss S et al. Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. 2015 Antimicrob. Agents Chemother. pmid:26392505
Agrawal V et al. A Case of Hypotension and Bradycardia Precipitated by Drug Interaction of Clarithromycin and Calcium-Channel Blocker. 2015 J Am Geriatr Soc pmid:26389998
Hauser G et al. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. 2015 Medicine (Baltimore) pmid:25929897
Yin SM et al. Disseminated Mycobacterium kansasii disease in complete DiGeorge syndrome. 2015 J. Clin. Immunol. pmid:26048260
Glocker EO The Need for Resistance Surveillance and Antimicrobial Susceptibility Testing of Helicobacter pylori. 2015 Digestion pmid:26372776
Bruhn DF et al. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. 2015 Sci Rep pmid:26365087
Ledwoń A et al. Multidrug therapy of Mycobacterium avium subsp. avium infection in experimentally inoculated budgerigars (Melopsittacus undulatus). 2015 Avian Pathol. pmid:26364975
Nakamura M et al. Clarithromycin ameliorates pulmonary inflammation induced by short term cigarette smoke exposure in mice. 2015 Pulm Pharmacol Ther pmid:26363279
Brusselle GG Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases? 2015 Thorax pmid:25870311
Picoli SU et al. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. 2014 May-Jun Rev. Inst. Med. Trop. Sao Paulo pmid:24878996
UÄŸurlu T et al. Optimization and evaluation of clarithromycin floating tablets using experimental mixture design. 2014 Mar-Apr Acta Pol Pharm pmid:25272652
Skvarc M et al. Multi locus sequence typing (MLST) used as a tool to confirm the ability of susceptible Helicobacter pylori strains to gain resistance to clarithromycin during eradication therapy. 2014 Jan-Feb Hepatogastroenterology pmid:24895826
Lara-Martín PA et al. Occurrence, distribution and partitioning of nonionic surfactants and pharmaceuticals in the urbanized Long Island Sound Estuary (NY). 2014 Mar. Pollut. Bull. pmid:24467856
Oztürk K et al. Diagnosis of helicobacter pylori infection. 2014 Turk J Gastroenterol pmid:25141328
Pathak V et al. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. 2014 Ann Am Thorac Soc pmid:24460438
Wu JY et al. Evidence-based recommendations for successful Helicobacter pylori treatment. 2014 Expert Rev Gastroenterol Hepatol pmid:24410470
Díaz Cuevas Z et al. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α]. 2014 Med Clin (Barc) pmid:23877097
Peedikayil MC et al. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. 2014 PLoS ONE pmid:24465624
Yoshida N et al. A cross-sectional investigation of the quality of selected medicines in Cambodia in 2010. 2014 BMC Pharmacol Toxicol pmid:24593851
Vu DH et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. 2014 Talanta pmid:24607103
Renvoisé A et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare. 2014 J. Clin. Microbiol. pmid:25274991
Tu S and Yang H [Progress in the treatment of Helicobacter pylori infection]. 2014 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:25269503
Wallace RJ et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. 2014 Chest pmid:24457542
Lee JW et al. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. 2014 Scand. J. Gastroenterol. pmid:24957849
Raffaldi I et al. An atypical deep neck infection in a two-year-old child. 2014 Infez Med pmid:24955801
Oh DH et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. 2014 J. Gastroenterol. Hepatol. pmid:24955448
Nishida T et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. 2014 World J. Gastroenterol. pmid:24764674